Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02108262 · ClinicalTrials.gov registry record · Phase 2
A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.
A Phase 2 study, sponsored by CSL Behring.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,267
- Enrollment target
NCT02108262: Completed Phase 2 study, sponsored by CSL Behring.
NCT02108262 is a Phase 2 study that has completed, run by CSL Behring. The registered enrollment target is 1,267 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (853% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02108262, a Phase 2 study, has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,267 participants
- Enrollment target
Study Summary
This is a multicenter randomized, double-blind, placebo-controlled, parallel-group, dose-ranging phase 2b study to investigate the hepatic and renal safety and tolerability of multiple dose administration of two dose levels of CSL112 compared with placebo in subjects with acute myocardial infarction (AMI).
Primary Outcome
A clinically important change in drug-induced liver injury is defined as a change (from baseline) in alanine aminotransferase (ALT) greater than 3 times the upper limit of normal (ULN) or a change in total bilirubin greater than 2 times ULN, that is confirmed upon repeat measurement.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL CSL112
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,267 participants |
| Start Date | 2014-08 |
| Est. Completion | 2016-03 |
| Phase | Phase 2 |
What the finished NCT02108262 record still lists
NCT02108262 is an interventional study that assigns participants to a tested intervention. Its 1,267 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (853% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02108262 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02108262 about?
NCT02108262 is a clinical study titled "A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.". This is a multicenter randomized, double-blind, placebo-controlled, parallel-group, dose-ranging phase 2b study to investigate the hepatic and renal safety and tolerability of multiple dose administration of two dose levels of CSL112 compared with placebo in subjects with acute myocardial infarction...
What is the current status of trial NCT02108262?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,267 participants. The study started on 2014-08. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02108262?
The interventions under investigation include: Placebo (BIOLOGICAL), CSL112 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02108262?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02108262's enrollment target sits among peer trials
1,267 15th of 2000 higher than 1,986 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06790641 · 1,270 participants · NA
Pathways to Perinatal Mental Health Equity
- NCT06876246 · 1,270 participants · NA
SBIR/ STTR Family Check-up Online
- NCT06119581 · 1,264 participants · Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- NCT03678025 · 1,273 participants · Phase 3
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia